

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Canigen Lepto 4, Suspension for Injection for Dogs

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each dose of 1 ml contains:

Active substances:

Inactivated *Leptospira* strains:

<i>L. interrogans</i> serogroup Canicola serovar Portland-verre (strain Ca-12-000)	3,550-7,100 U ¹
- <i>L. interrogans</i> serogroup Icterohaemorrhagiae serovar Copenhageni (strain Ic-02-001)	290-1,000 U ¹
- <i>L. interrogans</i> serogroup Australis serovar Bratislava (strain As-05-073)	500-1,700 U ¹
- <i>L. kirschneri</i> serogroup Grippotyphosa serovar Dadas (strain Gr-01-005)	650-1,300 U ¹

¹ Antigenic mass ELISA units.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Suspension for injection.

Colourless suspension.

4. CLINICAL PARTICULARS

4.1 Target species

Dogs.

4.2 Indications for use, specifying the target species

For active immunisation of dogs against:

- *L. interrogans* serogroup Canicola serovar Canicola to reduce infection and urinary excretion
- *L. interrogans* serogroup Icterohaemorrhagiae serovar Copenhageni to reduce infection and urinary excretion
- *L. interrogans* serogroup Australis serovar Bratislava to reduce infection
- *L. kirschneri* serogroup Grippotyphosa serovar Bananal/Lianguang to reduce infection and urinary excretion

Onset of immunity: 3 weeks.
Duration of immunity: 1 year.

4.3 Contraindications

None.

4.4 Special warnings for each target species

Vaccinate healthy animals only.

4.5 Special precautions for use

Special precautions for use in animals
Not applicable.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

Avoid accidental self-injection or contact with the eyes. In case of eye contact, rinse the eye(s) with water. In case of self-injection or ocular irritation, seek medical advice immediately and show the package leaflet or the label to the physician.

4.6 Adverse reactions (frequency and seriousness)

A mild and transient increase in body temperature (≤ 1 °C) has been observed very commonly in clinical studies for a few days after vaccination, with some pups showing less activity and/or a reduced appetite.

A small transient swelling at the site of injection (≤ 4 cm), which can occasionally be firm and painful on palpation, has been observed very commonly in clinical studies. Any such swelling will either have disappeared or be clearly diminished by 14 days post-vaccination.

Clinical signs of immune-mediated haemolytic anaemia, immune-mediated thrombocytopenia, or immune-mediated polyarthritis have been reported in very rare cases.

A transient acute hypersensitivity reaction may occur in very rare cases. Such reactions may evolve to a more severe condition (anaphylaxis), which may be life-threatening. If such reactions occur, appropriate treatment is recommended.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

4.7 Use during pregnancy, lactation or lay

Can be used during pregnancy.

4.8 Interaction with other medicinal products and other forms of interaction

Safety and efficacy data are available which demonstrate that this vaccine can be mixed and administered with vaccines in the Canigen range containing canine distemper virus strain Onderstepoort, canine adenovirus type 2 strain Manhattan LPV3, canine parvovirus strain 154 and/or canine parainfluenza virus strain Cornell components for subcutaneous administration where authorised.

The product information of the relevant Canigen vaccines should be consulted before administration of the mixed product. When mixed with these Canigen vaccines, the demonstrated safety and efficacy claims for Canigen Lepto 4 are no different from those described for Canigen Lepto 4 alone. When mixed with Canigen vaccines containing canine parainfluenza virus strain Cornell at annual revaccination, it has been established that there is no interference with the anamnestic response induced by the injectable canine parainfluenza virus component.

Safety and efficacy data are available which demonstrate that this vaccine can be administered on the same day but not mixed with vaccines in the Canigen range containing *Bordetella bronchiseptica* strain B-C2 and/or canine parainfluenza virus strain Cornell components for intranasal administration.

Safety data are available which demonstrate that this vaccine can be administered at the same time but not mixed with the inactivated vaccine of the Canigen range against *Bordetella bronchiseptica*. When this vaccine is administered in association with the inactivated vaccine of the Canigen range against *Bordetella bronchiseptica*, the demonstrated antibody response data and other immunity data of this vaccine are the same as when this vaccine is administered alone.

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

4.9 Amounts to be administered and administration route

Subcutaneous use.

Before use, ensure that the vaccine is at room temperature (15 °C – 25 °C).

Administer two vaccinations of 1 dose (1 ml) of vaccine with an interval of 4 weeks to dogs from 6 weeks of age onwards.

Vaccination scheme:

Basic vaccination: The first vaccination can be administered from 6 to 9^(*) weeks of age and the second vaccination from 10 to 13 weeks of age.

Revaccination: Dogs should be re-vaccinated annually with one dose (1 ml) of vaccine.

(*) In case of high level of maternally derived antibodies, first vaccination is recommended at 9 weeks of age.

For simultaneous use with Canigen vaccines where authorised:

1 dose of a Canigen vaccine containing canine distemper virus strain Onderstepoort, canine adenovirus type 2 strain Manhattan LPV3, canine parvovirus strain 154 and/or

canine parainfluenza virus strain Cornell components should be reconstituted with 1 dose (1 ml) of Canigen Lepto 4. The mixed vaccines should be at room temperature (15 °C – 25 °C) before they are administered by subcutaneous injection.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

No adverse reactions other than those mentioned in section 4.6 were observed after the administration of a double dose of vaccine. However, these reactions may be more severe and/or last longer. For example, local swelling, which can be up to 5 cm in diameter and which may take over 5 weeks to completely disappear, may be observed at the site of injection.

4.11 Withdrawal period

Not applicable.

5. IMMUNOLOGICAL PROPERTIES

Pharmacotherapeutic group: Immunologicals for *Canidae*, inactivated bacterial vaccine.
ATCvet code QI07AB01.

To stimulate active immunity in dogs against *L. interrogans* serogroup Canicola serovar Canicola, *L. interrogans* serogroup Icterohaemorrhagiae serovar Copenhageni, *L. interrogans* serogroup Australis serovar Bratislava, and *L. kirschneri* serogroup Grippotyphosa serovar Bananal/Lianguang.

In vitro and *in vivo* data in non-target species suggest that the vaccine may provide a degree of cross-protection against *L. interrogans* serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae and *L. kirschneri* serogroup Grippotyphosa serovar Grippotyphosa.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Sodium chloride
Potassium chloride
Disodium phosphate dihydrate
Potassium dihydrogen phosphate
Water for injections

6.2 Major incompatibilities

Do not mix with any other veterinary medicinal products except those mentioned in section 4.8.

6.3 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 21 months.
Shelf life after first opening the immediate packaging: use immediately.
Shelf life after reconstitution of Canigen vaccines according to directions: 45 minutes.

6.4 Special precautions for storage

Store in a refrigerator (2 °C – 8 °C).
Do not freeze.
Protect from light.

6.5 Nature and composition of immediate packaging

Type I glass vial of 1 ml (1 dose) closed with a halogenobutyl rubber stopper and sealed with a coded aluminium cap.

Pack sizes:

Plastic box with 10 vials of 1 ml (1 dose).
Plastic box with 50 vials of 1 ml (1 dose).

Not all pack sizes may be marketed.

6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

MSD Animal Health UK Limited
Walton Manor
Walton
Milton Keynes
Buckinghamshire
MK7 7AJ

8. MARKETING AUTHORISATION NUMBER


Vm 01708/5030

9. DATE OF FIRST AUTHORISATION

3 July 2015

10. DATE OF REVISION OF THE TEXT

October 2022

A handwritten signature in black ink, consisting of several loops and a final flourish.

Approved: 17 October 2022